Home/Pipeline/Authorized Generic of Nucynta® (tapentadol)

Authorized Generic of Nucynta® (tapentadol)

Pain Management

LaunchedLaunched (February 2026)

Key Facts

Indication

Pain Management

Phase

Launched

Status

Launched (February 2026)

Company

Hikma

About Hikma

Hikma is a multinational pharmaceutical company with a mission to improve global access to high-quality medicines. In 2025, it achieved a significant milestone by becoming the largest pharmaceutical company in the MENA region by sales, underscoring the strength of its Branded division. Its strategy focuses on leveraging distinct competitive advantages across its three business segments—Injectables, Generics, and Branded—while investing in R&D, manufacturing, and leadership to drive consistent, profitable growth, particularly in optimizing its Injectables business.

View full company profile

Therapeutic Areas

Oncology Supportive Care Infectious Disease Central Nervous System Cardiovascular Diabetes Pain Management Respiratory

Other Pain Management Drugs

Drug	Company	Phase	Status
Authorized Generic of Nucynta® ER (tapentadol)	Hikma	Launched	Launched (March 2026)
Intradermal Microneedle Patch	Isosceles Pharmaceuticals	Pre-clinical	Active
Non-addictive poppy-derived analgesic	Emerzene	Pre-clinical	Active
Pain R&D	Orion Pharma	Not Specified	Active
LymphaTouch Device	Lymphatouch	Commercial	Active
Generic Oxycodone ER (Oxycontin)	Natco Pharma	Launched	Marketed (via partner)
Generic Tapentadol ER	Hikma Pharmaceuticals	Approved	Launched (Mar 2026)
Generic Tapentadol	Hikma Pharmaceuticals	Approved	Launched (Feb 2026)